2025
Debate 1: Radical Prostatectomy For the Right Patient With High-Risk Prostate Cancer
Sundaresan V, Leapman M. Debate 1: Radical Prostatectomy For the Right Patient With High-Risk Prostate Cancer. Seminars In Radiation Oncology 2025, 35: 385-392. PMID: 40516973, DOI: 10.1016/j.semradonc.2025.05.001.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyRadical prostatectomyProstate cancerDeprivation therapyHigh riskEffect of long-term androgen-deprivation therapyLong-term androgen deprivation therapyAdequate randomized clinical trialsLong-term cancer controlHigh-risk prostate cancerRisk of gastrointestinal toxicityDisease-related survivalProportion of patientsDegrees of metastatic potentialResponse to treatmentRandomized clinical trialsCourse of treatmentSequence of surgeryLocal salvageRadiation therapySecondary malignanciesGastrointestinal toxicityInitial surgeryMultimodal treatmentHealth-related quality of lifePatterns of intra- and inter-tumor phenotypic heterogeneity in lethal prostate cancer
Roudier M, Gulati R, Sayar E, Patel R, Tratt M, Richards H, Cejas P, Gomez M, Qiu X, Xie Y, Hanratty B, Zaidi S, Zhao J, Adil M, Mittal C, Zhao Y, Dumpit R, Coleman I, Low J, Persse T, Galipeau P, Lee J, Tretiakova M, Chambers M, Vakar-Lopez F, True L, Perrone M, Lam H, Kollath L, Ding C, Harmon S, Cheng H, Yu E, Montgomery R, Hawley J, Lin D, Corey E, Schweizer M, Setty M, Ha G, Sawyers C, Morrissey C, Long H, Nelson P, Haffner M. Patterns of intra- and inter-tumor phenotypic heterogeneity in lethal prostate cancer. Journal Of Clinical Investigation 2025 PMID: 40493417, DOI: 10.1172/jci186599.Peer-Reviewed Original ResearchMetastatic prostate cancerLethal prostate cancerProstate cancerPhenotypic heterogeneityMetastatic prostate cancer patientsMolecularly heterogeneous diseaseTumor cell populationIntra-tumor heterogeneityCellular proliferation rateMetastatic sitesSingle-cell sequencing studiesMolecular subtypesClinical featuresTumor heterogeneityTumor phenotypeTumor samplesHeterogeneous diseaseClinical managementAnatomical sitesTherapeutic approachesSubtype heterogeneityPatientsTissue-basedCell populationsProliferation rateAndrogen pathway gene expression and response to hormonal therapy in prostate cancer (SWOG S1216).
Pinski J, Ingles S, Manojlovic Z, Xiong S, Weisenberger D, Goldkorn A, McConkey D, Lara P, Hussain M, Quinn D, Thompson I, Lerner S, Dorff T, Agarwal N. Androgen pathway gene expression and response to hormonal therapy in prostate cancer (SWOG S1216). Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e17109.Peer-Reviewed Original ResearchMetastatic castration-sensitive prostate cancerProgression free survivalResponse to androgen deprivation therapyAndrogen metabolism genesAndrogen deprivation therapyPrimary prostate tumorsProstate cancerPSA responsePSA-CRDeprivation therapyProstate tumorsMolecular features of prostate cancerCastration-sensitive prostate cancerAnalysis of progression free survivalFeatures of prostate cancerResponse to hormonal therapyDays of follow-upAndrogen receptor inhibitorsTumor gene expression profilesUnder-expressedExpression levelsFree survivalAssociation of expression levelsHormone therapyTumor blocksCombined genomic profiling of cell-free DNA (cfDNA) and circulating tumor cell DNA (ctcDNA) in S1802, a prospective phase 3 trial for metastatic prostate cancer (mHSPC).
Bsteh D, Buckley J, Mitchell S, Ostrow D, Parmentier J, Jahan S, Sadis S, Smith J, NI J, Peng X, McConkey D, Dorff T, Lerner S, Aparicio A, Chapin B, Duddalwar V, Triche T, Goldkorn A. Combined genomic profiling of cell-free DNA (cfDNA) and circulating tumor cell DNA (ctcDNA) in S1802, a prospective phase 3 trial for metastatic prostate cancer (mHSPC). Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e17111.Peer-Reviewed Original ResearchProspective phase 3 trialsSingle nucleotide variantsCopy number variantsPhase 3 trialProstate cancerTime pointsProstate cancer-relevant genesCirculating tumor cell DNALiquid biopsy componentsMetastatic prostate cancerMultiple time pointsIon Reporter softwareRecurrent copy number variantsTumor cell DNACell-free DNASingle tube of bloodCancer-relevant genesThermo FisherTubes of bloodPrimary tumorSystemic therapyDefinitive treatmentCtcDNAIndeterminate significancePreservation tubesGenomic landscape and clinical characteristics of patients (pts) with neuroendocrine prostate cancer (NEPC) with or without aggressive variant prostate cancer characterized by molecular signature (AVPC-MS).
Ebrahimi H, Barragan-Carrillo R, Zugman M, Jaime-Casas S, Shah K, Castro D, Mercier B, Zengin Z, Meza L, Li X, Hsu J, Zang P, Dizman N, Nguyen C, Tripathi A, Dorff T, Pal S, Chehrazi-Raffle A. Genomic landscape and clinical characteristics of patients (pts) with neuroendocrine prostate cancer (NEPC) with or without aggressive variant prostate cancer characterized by molecular signature (AVPC-MS). Journal Of Clinical Oncology 2025, 43: 5087-5087. DOI: 10.1200/jco.2025.43.16_suppl.5087.Peer-Reviewed Original ResearchNeuroendocrine prostate cancerTumor mutational burdenClinical characteristicsProstate cancerAggressive variant prostate cancerPrevalence of genomic alterationsHigh tumor mutational burdenClinical characteristics of patientsAndrogen receptor inhibitorsPersonalized treatment approachesFisher's exact testCharacteristics of patientsMicrosatellite instability-highIndividuals aged >Mutational burdenPathological confirmationPTEN alterationsReceptor inhibitorsNo significant differenceAggressive subtypeGenomic surrogateExact testGenomic alterationsClinical trialsTwo-proportion z-testAssociation between prostate radiation therapy and survival among patients with metastatic prostate cancer by extent of disease burden.
Palencia P, Zhao X, Kandala K, Smani S, Sivanesan N, Cavallo J, Leapman M. Association between prostate radiation therapy and survival among patients with metastatic prostate cancer by extent of disease burden. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e17123.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyProstate radiation therapyMetastatic prostate cancerOverall survivalRadiation therapyProstate cancerM1c diseaseTreatment modalitiesRT to ADTTreated with androgen deprivation therapyAssociated with improved overall survivalHormone-sensitive prostate cancerAssociated with poor overall survivalPrimary local therapyExternal beam radiotherapyGleason grade groupCompare overall survivalNational Cancer DatabaseProstate cancer metastasisLog-rank testDisease burdenKaplan-Meier curvesCox proportional hazards modelsLow disease burdenBarriers to germline genetic testing in advanced prostate cancer: Survey results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium (PCCTC).
Sokolova A, Paller C, Antonarakis E, Barata P, Berchuck J, Darst B, Giri V, Graffeo R, Hathaway F, Kwon D, Loeb S, McKay R, Reichert Z, Ribeiro M, Sachdeva A, Stadler W, Stein M, Taplin M, Weg E, Cheng H. Barriers to germline genetic testing in advanced prostate cancer: Survey results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium (PCCTC). Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e17073.Peer-Reviewed Original ResearchGermline genetic testingProstate Cancer Clinical Trials ConsortiumHigh-risk localized prostate cancerGermline testingGenetic testingLocalized prostate cancerAdvanced prostate cancerProstate cancer patientsProstate cancerGenetic counselorsParticipating physiciansClinical workflowMPCa patientsPost-test counsellingGenetic test resultsFree-text commentsSurvey of physiciansMetastatic prostate cancerPhysician uptakeTesting uptakeGenetics educationPerceived barriersClinic flowClinical Trials ConsortiumFamily historyUtilizing peer educators to increase genetic testing for prostate cancer among black males: results of a randomized controlled trial
Leader A, Godbolt J, Crumpler N, Gross L, Hartman R, Keith S, Giri V. Utilizing peer educators to increase genetic testing for prostate cancer among black males: results of a randomized controlled trial. Journal Of The National Medical Association 2025 PMID: 40447525, DOI: 10.1016/j.jnma.2025.05.005.Peer-Reviewed Original ResearchPeer educatorsGenetic testingBenefits of genetic testingRates of genetic testingGroup-based discussionsBlack malesIncreased genetic testingPeer-based strategiesProstate cancerRandomized controlled trialsDecisional conflictIntervention armEducational interventionCommunity settingsEndpoint surveyControl armEducational materialsGenetic counselingDecreased intentionIncreased intentionStudy armsInformation materialsInterventionEducationComplex decisionsGermline testing for prostate cancer: current state and opportunities for enhanced access
Loeb S, Vadaparampil S, Giri V. Germline testing for prostate cancer: current state and opportunities for enhanced access. EBioMedicine 2025, 116: 105705. PMID: 40398351, PMCID: PMC12148599, DOI: 10.1016/j.ebiom.2025.105705.Peer-Reviewed Original ResearchConceptsGermline testingProstate cancerHereditary cancer assessmentFamily cancer historyHereditary cancer syndromesGenetic counseling programsCancer-related outcomesProstate cancer careCancer historyCancer syndromesDelivery modelsAdvanced prostate cancerMetastatic prostate cancerHigh-risk featuresImplementation strategiesBenefits of GTCounseling programCancer assessmentEnhanced accessTested patientsDisparitiesPCA-relatedPatientsGuidelinesProstateProstate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysis
Miszczyk M, Fazekas T, Rajwa P, Matsukawa A, Tsuboi I, Leapman M, Kramer G, Hussain M, Merseburger A, Briganti A, D'Amico A, Gillessen S, Saad F, Shariat S. Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysis. European Urology Focus 2025 PMID: 40379533, DOI: 10.1016/j.euf.2025.03.019.Peer-Reviewed Original ResearchAndrogen receptor pathway inhibitorsPSA responseProstate-specific antigen reductionAssociated with better OSProstate-specific antigenAndrogen deprivation therapyCastration-resistant PCOverall survivalProstate cancerTreated with androgen deprivation therapyHazard ratioMetastatic castration-resistant PCMetastatic hormone-sensitive PCNonmetastatic castration-resistant PCProstate-specific antigen responsePathway inhibitorBaseline PSA measurementHormone-sensitive PCUndetectable PSA levelsAdvanced prostate cancerAssociated with OSRandom-effects meta-analysesDeprivation therapyPSA levelsPSA measurementsFactors Affecting Genomic Testing in Prostate Cancer: Results From the Decision-Making, Experience, and Confidence In Determining Genomic Evaluation (DECIDE) Survey
Bitting R, McNair C, Wyatt A, Vandekerkhove G, Choi T, Leader A, Blanding-Godbolt J, Gross L, Hamade K, Halabi S, Giri V. Factors Affecting Genomic Testing in Prostate Cancer: Results From the Decision-Making, Experience, and Confidence In Determining Genomic Evaluation (DECIDE) Survey. JCO Precision Oncology 2025, 9: e2400821. PMID: 40373262, DOI: 10.1200/po-24-00821.Peer-Reviewed Original ResearchConceptsGenomic testingTraining of health care professionalsHereditary cancer assessmentSomatic genomic testingHealth care providersHealth care professionalsAcademic medical centerLack of educationSelf-confidenceProvider confidenceCare providersCare professionalsCommon barriersSurvey domainsProstate cancerPractical barriersMultiple-response questionsTest utilizationMedical oncologistsMedical CenterEnhanced implementationDecision-making factorsProvidersDecision-makingPercentage of responsesImpact of Concomitant Hormone Therapy on the Diagnostic Performance of 18F‐Piflufolastat PET/CT in Prostate Cancer Patients: A Sub‐Group Analysis of OSPREY Cohort B
Saperstein L, Rowe S, Gorin M, Pienta K, Siegel B, Morris M, Baskaran S, Stambler N, DiPippo V, Denes B. Impact of Concomitant Hormone Therapy on the Diagnostic Performance of 18F‐Piflufolastat PET/CT in Prostate Cancer Patients: A Sub‐Group Analysis of OSPREY Cohort B. The Prostate 2025, 85: 1005-1015. PMID: 40320701, PMCID: PMC12211537, DOI: 10.1002/pros.24909.Peer-Reviewed Original ResearchConceptsProstate-specific antigenPositive predictive valueMetastatic prostate cancerCohort B patientsConcomitant HTConcurrent HTHormone therapyDiagnostic performanceTestosterone levelsB patientsProstate cancerCohort BBaseline serum prostate-specific antigenMedian baseline prostate-specific antigenBaseline prostate-specific antigenMedian prostate-specific antigenElevated prostate-specific antigenSerum prostate-specific antigenImpact of hormone therapyConcomitant hormonal therapySuspected local recurrenceProstate cancer patientsSub-group analysisMedian exposure durationMetastatic diseaseTissue-based gene expression testing in localized prostate cancer
Sivanesan N, Diaz G, Sprenkle P. Tissue-based gene expression testing in localized prostate cancer. Current Opinion In Urology 2025, 35: 432-438. PMID: 40314067, DOI: 10.1097/mou.0000000000001289.Peer-Reviewed Original ResearchConceptsLocalized prostate cancerTissue-based genomic testingProstate cancerRisk stratificationGenomic testingManagement of localized prostate cancerProstate cancer risk stratificationIdentified high-risk patientsClinically significant cancerProstate cancer outcomesImpact of genomic testingHigh-risk patientsAssess tumor aggressivenessLow-risk casesGenomic assaysGene expression testsTreatment decision-makingPSA levelsGleason scoreSignificant cancerOncotype DXTumor aggressivenessTherapeutic choiceReduce overtreatmentProspective studyProstate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
Carlsson S, Barata P, Bryce A, George D, Gillessen S, Loeb S, Montgomery B, Morris D, Riaz I, Palapattu G, Schoen M, Washington Iii S, Cornell B, Levine R, Aggarwal P, McGowan T, Cotter M, Thompson B, Devgan G, Russell D, Kuperman G, Lenero E, Iwata K, Miyahira A, Soule H, Carithers G, Oh W, Agarwal N. Prostate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer. JCO Oncology Practice 2025, op2500050. PMID: 40315399, DOI: 10.1200/op-25-00050.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerProstate Cancer FoundationHormone-sensitive prostate cancerCombination therapyProstate cancerPatients treated with combination therapyAndrogen receptor pathway inhibitorsBenefit of combination therapyQuality of lifeSignificant survival improvementUrban-dwelling patientsPreserving quality of lifeEnhanced survival outcomesGuideline-concordant careMeta-analysesRandomized controlled trialsDeprivation therapyEvidence-based therapiesSurvival outcomesTreatment utilization patternsSurvival improvementClinical trialsGlobal RegistryPathway inhibitorCombined treatmentEnzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer
Azad A, Petrylak D, Iguchi T, Shore N, Villers A, Gomez-Veiga F, Alcaraz A, Alekseev B, Szmulewitz R, Holzbeierlein J, Rosbrook B, Ma J, Zohren F, El-Chaar N, Haas G, Stenzl A, Armstrong A. Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer. JAMA Network Open 2025, 8: e258751. PMID: 40332939, PMCID: PMC12059972, DOI: 10.1001/jamanetworkopen.2025.8751.Peer-Reviewed Original ResearchConceptsMetastatic hormone-sensitive prostate cancerProstate-specific antigen levelRadiographic progression-free survivalUndetectable prostate-specific antigenAndrogen deprivation therapyProstate-specific antigenProstate-specific antigen declineClinical outcomesOverall survivalProstate cancerClinical trialsHazard ratioPatients treated with enzalutamideHormone-sensitive prostate cancerPhase 3 randomized clinical trialAssociated with improved survivalStudy enrollmentProgression-free survivalMetastatic prostate cancerRadiographic disease progressionClinical end pointsPost hoc secondary analysisRandomized clinical trialsReduced riskSecondary analysisConditional Convolution of Clinical Data Embeddings for Multimodal Prostate Cancer Classification
Zhong J, Chen F, Chen L, Shung D, Onofrey J. Conditional Convolution of Clinical Data Embeddings for Multimodal Prostate Cancer Classification. 2025, 00: 1-5. DOI: 10.1109/isbi60581.2025.10981307.Peer-Reviewed Original ResearchConvolutional neural networkGleason scoreProstate cancerClinical dataMultiparametric magnetic resonance imagingPredicting Gleason scoreClinical informationCurrent deep learning approachesPatient clinical dataMagnetic resonance imagingDeep learning approachNon-invasive diagnosisAccurate risk predictionData embeddingCNN kernelsMRI scansConditional convolutionPublic datasetsResonance imagingNeural networkProstate cancer classificationData modalitiesLearning approachBaseline modelGS prediction accuracyGermline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline Clinical Insights.
Giri V, Rumble R, Yu E, Lu K. Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline Clinical Insights. JCO Oncology Practice 2025, op2500186. PMID: 40239123, DOI: 10.1200/op-25-00186.Peer-Reviewed Original ResearchAdvances in Current Treatment Paradigms for Metastatic Hormone-Sensitive Prostate Cancer
Smani S, DuBois J, Ajjawi I, Sohoni N, Choksi A, Lokeshwar S, Kim I, Renzulli J. Advances in Current Treatment Paradigms for Metastatic Hormone-Sensitive Prostate Cancer. Journal Of Clinical Medicine 2025, 14: 2565. PMID: 40283395, PMCID: PMC12028174, DOI: 10.3390/jcm14082565.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyAndrogen receptor signaling inhibitorsHormone-sensitive prostate cancerCombination therapyProstate cancerHigh-volume metastatic diseaseProgression to castration resistancePSMA PET-CTLow-volume diseaseOverall survival benefitCurrent treatment paradigmDetection of metastasesBalance treatment efficacyPersonalized treatment strategiesOptimal treatment selectionStandard of careCytoreductive prostatectomyDoublet therapyPrecision-based approachesTriplet therapyCastration resistanceDeprivation therapyMetastatic diseaseRadiation therapyDelivering on the Promise of Precision Oncology in Prostate Cancer: Prediagnostic Strategies, Postdiagnostic Applications, and Future Directions. A Narrative Review
Diaz G, Palencia P, Leapman M. Delivering on the Promise of Precision Oncology in Prostate Cancer: Prediagnostic Strategies, Postdiagnostic Applications, and Future Directions. A Narrative Review. Journal Of Urologic Oncology 2025, 23: 4-13. DOI: 10.22465/juo.255000120006.Peer-Reviewed Original ResearchLocalized prostate cancerProstate cancerPrecision oncologyManagement of localized prostate cancerRefine risk predictionActive surveillance protocolsSurveillance protocolsTumor heterogeneityTreatment selectionPatient variablesOptimal outcomesRisk assessment toolBiomarker discoveryOvertreatmentOncologyCancerRisk predictionBiological characteristicsProstateBeyond Phecodes: leveraging PheMAP to identify patients lacking diagnosis codes in electronic health records
Yan C, Grabowska M, Thakkar R, Dickson A, Embí P, Feng Q, Denny J, Kerchberger V, Malin B, Wei W. Beyond Phecodes: leveraging PheMAP to identify patients lacking diagnosis codes in electronic health records. Journal Of The American Medical Informatics Association 2025, 32: 1007-1014. PMID: 40156924, PMCID: PMC12089765, DOI: 10.1093/jamia/ocaf055.Peer-Reviewed Original ResearchConceptsElectronic health recordsSensorineural hearing lossHearing lossDiagnosis codesHealth recordsPhenotype risk scorePatient recordsClinical terminologyProstate cancerType 2 diabetes mellitusRisk scoreDementiaExpert reviewT2DMPHEMAPPhenotype patientsProstatePatientsCancerPositive casesPhecodesResearch reliabilityDiagnosisRecordsPhenotype
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply